Senolytic Therapy at Longevity Clinics (2026)
Senolytic therapy uses drugs or natural compounds to selectively destroy senescent cells — also called "zombie cells." These are cells that have stopped dividing but refuse to die, accumulating with age and secreting toxic proteins (the senescence-associated secretory phenotype, or SASP) that drive inflammation, tissue degradation, and age-related disease. By clearing these cells, senolytic therapy aims to reduce the biological burden of aging at its source.
How Senolytic Therapy Works
Senescent cells resist normal programmed cell death (apoptosis) by upregulating anti-death proteins (BCL-2, BCL-XL, PI3K/AKT). Senolytics work by inhibiting these survival pathways, allowing senescent cells to finally undergo apoptosis. The most studied combination is dasatinib (a leukemia drug) plus quercetin (a plant flavonoid), known as D+Q. Dasatinib targets senescent fat cell precursors, while quercetin targets senescent endothelial cells. Other senolytics include fisetin (a strawberry compound), navitoclax, and emerging FOXO4-DRI peptides.
Scientific Evidence
The evidence base is growing rapidly. The landmark 2018 Nature Medicine paper by Kirkland and Tchkonia showed that D+Q extended healthspan in aged mice by 36%. The first human senolytic trial (Mayo Clinic, 2019) showed improved physical function in patients with diabetic kidney disease. The 2023 TOSS trial demonstrated that D+Q reduced senescent cell burden in patients with Alzheimer's disease. A 2024 Lancet Healthy Longevity review noted that "senolytics are among the most promising translational geroscience interventions." Multiple Phase 2 trials are underway for specific age-related conditions.
Pricing Overview
Senolytic therapy is not yet commercially standardized. Oral D+Q protocols (available through some longevity clinics) cost USD 200–500 per treatment cycle (typically 3 days of dosing, repeated quarterly). Fisetin supplementation costs USD 30–100/month. More advanced senolytic programs at specialized clinics, including senescent cell burden testing and monitoring, range from USD 2,000–10,000 per year.
Clinic Availability
We are currently auditing which clinics in our directory offer Senolytic Therapy. Check individual clinic profiles or browse all clinics to find providers.
Frequently Asked Questions
Common questions about Senolytic Therapy at longevity clinics.
Can I take senolytics as supplements?
Quercetin and fisetin are available as over-the-counter supplements. However, the D+Q protocol uses dasatinib, a prescription chemotherapy drug that requires medical supervision. Self-supplementation with quercetin or fisetin alone may not achieve the same senescent cell clearance as the D+Q combination. Consult with a longevity physician before starting any senolytic protocol.
How often should senolytics be taken?
The "hit-and-run" dosing strategy is most common: 2–3 consecutive days of treatment, repeated every 1–3 months. This approach minimizes side effects while maximizing senescent cell clearance. The optimal frequency is still being researched and may vary by age, health status, and senescent cell burden.
Are senolytics FDA-approved for anti-aging?
No senolytic therapy is FDA-approved specifically for anti-aging or longevity. Dasatinib is FDA-approved for leukemia. Quercetin and fisetin are available as dietary supplements. Clinical trials are investigating senolytics for specific age-related conditions (Alzheimer's, osteoarthritis, kidney disease), which could eventually support broader longevity claims.
What are the side effects of senolytic therapy?
Short-course D+Q is generally well-tolerated. Reported side effects include mild fatigue, transient decreases in blood cell counts, and occasional gastrointestinal discomfort. Dasatinib at cancer doses has more significant side effects, but senolytic protocols use much lower, intermittent doses. Long-term safety data is still being collected through ongoing clinical trials.